REG - Abingdon Health PLC - Result of Meeting and TVR

Abingdon HealthAnnouncement

30/10/2025 09:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251030:nRSd5023Fa&default-theme=true

RNS Number : 5023F  Abingdon Health PLC  30 October 2025

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

 

 

30 October 2025

 

Abingdon Health plc

 

("Abingdon Health", the "Group" or the "Company")

 

Result of General Meeting and Total Voting Rights

 

Abingdon Health plc (AIM: ABDX) a leading international developer,
manufacturer and regulatory services provider for rapid diagnostic tests and
med-tech, is pleased to announce that, at the General Meeting held earlier
today, the Resolutions set out in the Notice of General Meeting contained in
the Circular dated 14 October 2025 were duly passed.

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings given to them in the Company's announcement made at 5:04
p.m. on 13 October 2025, unless the context requires otherwise.

 

Result of Meeting

 

Details of the results of the voting at the General Meeting, including the
number of votes for and against the Resolutions proposed, and the number of
votes withheld, are set out below. The Resolutions were proposed and passed as
one ordinary resolution and one special resolution.

 

 Resolution                               For                            Against                     Withheld
                                          Votes         % of votes cast  Votes      % of votes cast  Votes
 1.  Authority to allot shares             81,408,856    99.82            144,292    0.18             23,747
 2. Disapplication of pre-emption rights   81,247,542    99.66            273,311    0.34             56,042

 

The total number of votes received were 163,074,001. Votes withheld are not
votes in law and so have not been included in the calculation of the
proportion of votes for and against a resolution.

 

The passing of the Resolutions is one of the conditions to completion of the
Fundraising, and as a result of the votes cast in their favour, that
particular condition has been satisfied. Completion of the Fundraising remains
conditional upon Admission, which is expected to occur on or around 31 October
2025.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for admission of the
57,441,821 new Ordinary Shares to trading on AIM ("Admission"). It is expected
that Admission will become effective and dealings in the new Ordinary Shares
will commence at 8.00 a.m. on or around 31 October 2025.

 

Following Admission, the Company's issued ordinary share capital will comprise
251,072,642 Ordinary Shares, with no shares held in treasury. Therefore, the
number of Total Voting Rights in the Company will be 251,072,642, and this
figure may be used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the voting rights of the Company under the
FCA's Disclosure Guidance and Transparency Rules.

 

 

Director and PDMR Shareholdings

 

Following completion of the Fundraising, the following Directors are
interested in the following:

 

 Director / PDMR      Position                         Existing beneficial interest in Ordinary Shares  % of current share capital  New Ordinary Shares subscribed for  Ordinary Shares after Fundraise  % of Enlarged Share Capital
 Chris                Executive Chairman               13,178,467                                       6.8                         500,000                             13,678,467                       5.4%

Hand
 Candice Vendettuoli  Quality and Regulatory Director  -                                                -                           33,333                              33,333                           0.01%

 

 

 

 

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR

 Tom Hayes, Chief Financial Officer

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Darshan Patel / Jacob Walker (Corporate Finance)
 Nick Searle / Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Chris Hand

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)           Volume(s)
                                                                                     6 pence per share  500,000

 d)   Aggregated information

      - Aggregated volume                                          500,000

      - Price                                                      6 pence per share

 e)   Date of the transaction                                      30 October 2025

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Candice Vendettuoli

 2    Reason for the notification

 a)   Position/status                                              Quality and Regulatory Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)           Volume(s)
                                                                                     6 pence per share  33,333

 d)   Aggregated information

      - Aggregated volume                                          33,333

      - Price                                                      6 pence per share

 e)   Date of the transaction                                      30 October 2025

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
expertise offers lateral flow product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format.  Abingdon Health has the internal capabilities to take lateral
flow projects, in areas such as infectious disease and clinical testing,
including companion diagnostics, animal health and environmental testing, from
initial concept through to routine manufacturing; from "idea to commercial
success".  Abingdon Analytical Ltd offers performance evaluation for lateral
flow and other in vitro diagnostic assays from its Doncaster laboratory.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMFIFVAIALIVIE



            Copyright 2019 Regulatory News Service, all rights reserved